Gate Neurosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gateneuro.com
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Pharmacokinetics of GATE-251 in Fasted or Fed State
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Drug: Zelquistinel 3 mgDrug: Zelquistinel 10 mg
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Gate Neurosciences, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT07099989
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Gate Neurosciences, Inc
- Target Recruit Count
- 164
- Registration Number
- NCT06547489
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham-Huntsville, Huntsville, Alabama, United States
🇺🇸Wr-Pri, Llc, Encino, California, United States
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Gate Neurosciences, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT05597241
- Locations
- 🇺🇸
Woodland Research Northwest, Rogers, Arkansas, United States
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Gate Neurosciences, Inc
- Target Recruit Count
- 18
- Registration Number
- NCT04618263
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
AGN-241751 in the Treatment of Major Depressive Disorder
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Gate Neurosciences, Inc
- Target Recruit Count
- 226
- Registration Number
- NCT03726658
- Locations
- 🇺🇸
Alea Research, Phoenix, Arizona, United States
🇺🇸Collaborative Neuroscience Network, LLC, Garden Grove, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
- Prev
- 1
- 2
- Next